Diabetes Care:高海拔活动改善血糖血脂控制

2012-07-31 张一宸 医学论坛网

  《糖尿病护理》(Diabetes Care)杂志7月24日在线刊登一项研究表明,与运动训练相比,高海拔活动对2型糖尿病患者更有帮助,在控制血糖的情况下,高海拔活动能够改善患者血糖、血脂和空腹胰岛素浓度。   在经过6个月运动训练后,13例2型糖尿病患者参加在摩洛哥图卜卡勒顶峰为期12天的活动(海拔4167 m),分析其能量消耗、体重、血糖、空腹胰岛素、血脂和HbA1c变化。结果发现。运动训练

  《糖尿病护理》(Diabetes Care)杂志7月24日在线刊登一项研究表明,与运动训练相比,高海拔活动对2型糖尿病患者更有帮助,在控制血糖的情况下,高海拔活动能够改善患者血糖、血脂和空腹胰岛素浓度。

  在经过6个月运动训练后,13例2型糖尿病患者参加在摩洛哥图卜卡勒顶峰为期12天的活动(海拔4167 m),分析其能量消耗、体重、血糖、空腹胰岛素、血脂和HbA1c变化。结果发现。运动训练降低空腹血糖[(−0.7±0.9)mmol/L,P=0.026]增加运动能力[ (+0.3±0.3)W/kg,P=0.005]。而高海拔活动降低空腹胰岛素[(−3.8±3.2)μU/L,P=0.04],总胆固醇[(−0.7±0.8)mmol/L,P=0.008]和LDL胆固醇[(−0.5±0.6)mmol/L,P=0.007]。

  链接:de Mol P, Fokkert MJ, de Vries ST, de Koning EJ, Dikkeschei BD, Gans RO, Tack CJ, Bilo HJ.Metabolic Effects of High Altitude Trekking in Patients With Type 2 Diabetes.Diabetes Care. 2012 Jul 24

  



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942160, encodeId=c94a1942160c8, content=<a href='/topic/show?id=c489102465b4' target=_blank style='color:#2F92EE;'>#高海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102465, encryptionId=c489102465b4, topicName=高海拔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Thu May 30 10:51:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759165, encodeId=bfca1e59165b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 14 08:51:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688373, encodeId=b79a16883e3fe, content=<a href='/topic/show?id=df81656161b' target=_blank style='color:#2F92EE;'>#海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65616, encryptionId=df81656161b, topicName=海拔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1c128575901, createdName=12498974m60暂无昵称, createdTime=Mon Feb 04 18:51:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900974, encodeId=ee1719009e43e, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Mar 06 20:51:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636533, encodeId=5bcd163653384, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 15 18:51:00 CST 2013, time=2013-05-15, status=1, ipAttribution=)]
    2013-05-30 zsyan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942160, encodeId=c94a1942160c8, content=<a href='/topic/show?id=c489102465b4' target=_blank style='color:#2F92EE;'>#高海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102465, encryptionId=c489102465b4, topicName=高海拔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Thu May 30 10:51:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759165, encodeId=bfca1e59165b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 14 08:51:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688373, encodeId=b79a16883e3fe, content=<a href='/topic/show?id=df81656161b' target=_blank style='color:#2F92EE;'>#海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65616, encryptionId=df81656161b, topicName=海拔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1c128575901, createdName=12498974m60暂无昵称, createdTime=Mon Feb 04 18:51:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900974, encodeId=ee1719009e43e, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Mar 06 20:51:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636533, encodeId=5bcd163653384, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 15 18:51:00 CST 2013, time=2013-05-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942160, encodeId=c94a1942160c8, content=<a href='/topic/show?id=c489102465b4' target=_blank style='color:#2F92EE;'>#高海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102465, encryptionId=c489102465b4, topicName=高海拔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Thu May 30 10:51:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759165, encodeId=bfca1e59165b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 14 08:51:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688373, encodeId=b79a16883e3fe, content=<a href='/topic/show?id=df81656161b' target=_blank style='color:#2F92EE;'>#海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65616, encryptionId=df81656161b, topicName=海拔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1c128575901, createdName=12498974m60暂无昵称, createdTime=Mon Feb 04 18:51:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900974, encodeId=ee1719009e43e, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Mar 06 20:51:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636533, encodeId=5bcd163653384, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 15 18:51:00 CST 2013, time=2013-05-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942160, encodeId=c94a1942160c8, content=<a href='/topic/show?id=c489102465b4' target=_blank style='color:#2F92EE;'>#高海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102465, encryptionId=c489102465b4, topicName=高海拔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Thu May 30 10:51:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759165, encodeId=bfca1e59165b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 14 08:51:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688373, encodeId=b79a16883e3fe, content=<a href='/topic/show?id=df81656161b' target=_blank style='color:#2F92EE;'>#海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65616, encryptionId=df81656161b, topicName=海拔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1c128575901, createdName=12498974m60暂无昵称, createdTime=Mon Feb 04 18:51:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900974, encodeId=ee1719009e43e, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Mar 06 20:51:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636533, encodeId=5bcd163653384, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 15 18:51:00 CST 2013, time=2013-05-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1942160, encodeId=c94a1942160c8, content=<a href='/topic/show?id=c489102465b4' target=_blank style='color:#2F92EE;'>#高海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102465, encryptionId=c489102465b4, topicName=高海拔)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Thu May 30 10:51:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759165, encodeId=bfca1e59165b4, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Aug 14 08:51:00 CST 2012, time=2012-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688373, encodeId=b79a16883e3fe, content=<a href='/topic/show?id=df81656161b' target=_blank style='color:#2F92EE;'>#海拔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65616, encryptionId=df81656161b, topicName=海拔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1c128575901, createdName=12498974m60暂无昵称, createdTime=Mon Feb 04 18:51:00 CST 2013, time=2013-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900974, encodeId=ee1719009e43e, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Mar 06 20:51:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636533, encodeId=5bcd163653384, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 15 18:51:00 CST 2013, time=2013-05-15, status=1, ipAttribution=)]

相关资讯

Lancet:早期积极控制血糖是治疗糖尿病前期的关键

具有里程碑意义的“糖尿病预防计划(Diabetes Prevention Program,DPP)”的最新分析显示,及早让糖尿病前期患者恢复正常的血糖水平是预防疾病进展的关键所在,无论是通过生活方式干预还是药物治疗来实现。   美国科罗拉多大学的Leigh Perreault 博士及其同事报告称,事实上在参与DPP的受试者中,即便血糖水平短暂恢复正常也与糖尿病风险显著降低相关。DPP

综合干预治疗糖尿病合并冠心病

   糖尿病远非是血糖问题,糖尿病所引发的一系列并发症,尤其是大血管疾病,其是糖尿病防治的核心。因此,严格控制血糖,且全面控制多种危险因素,是糖尿病合并冠心病的防治关键。   强化血糖控制:干预共同病因   2010年,美国糖尿病学会(ADA)将糖化血红蛋白(HbA1c)≥6.5%作为糖尿病的诊断标准之一。与ADA不同的是,2011年美国内分泌医师协会(AACE)不建议将HbA1c作

Lancet:控制血糖以外的糖尿病管理

  多国学者的一项研究表明,在二甲双胍控制不佳的2型糖尿病患者中添加基础胰岛素为可选方案。实现疾病早期的最佳血糖控制有可能带来远期获益。论文于2012年6月9日在线发表于《柳叶刀》(Lancet)杂志。    在伴有2型糖尿病的患者中,二肽基肽酶-4(DPP-4)抑制剂为二甲双胍治疗后的可选二线治疗药物,基础胰岛素则被推荐为替代药物。此项平行组、随机对照、开放标签试验二甲双胍经治人群为受试者;受

Arch Neurol:糖尿病患者血糖控制不佳加速认知下降

  《神经病学文献》杂志(Arch Neurol)2012年6月18日在线发表了一项糖尿病(DM)和血糖控制情况与无痴呆老年患者认知功能之间关系的研究结果。这项来自于美国加州大学的前瞻性队列研究发现,DM和血糖控制不佳患者与其认知功能低下有关,且认知功能降低更快,研究提示DM的严重性加速了其认知功能衰退。   研究数据来源于2个社区诊所的健康、老龄化和身体成份研究,共涉及3,069例老年人(平均

换用不同种类胰岛素血糖改善情况和低血糖风险无差异

  近期一项名为SWING的多国研究报告,在2型糖尿病患者中,从短效人胰岛素换用速效胰岛素类似物(H-A)后,糖尿病相关直接医疗费用略增加,而反之(A-H)费用则略降低。但两种换药方法在改善HbA1c和降低低血糖风险等方面均无明显差异。研究4月9日在线发表于《糖尿病研究与临床实践》(Diabetes Res Clin Pract)。   该项在欧洲9个国家开展的前瞻性观察性研究纳入2389例2型

BMJ:糖尿病问诊技巧培训未能改善1型糖尿病儿童血糖控制(DEPICTED研究)

  英国研究者进行的一项聚类随机对照临床试验(DEPICTED研究)表明,通过简单的集体培训问诊技巧的方式不能改善糖尿病专科诊所儿童的血糖控制。该研究结果4月26日发表于《英国医学杂志》(BMJ)。   研究者为了评价面向儿科糖尿病团队的问诊技巧培训项目对血糖控制的效果,在26个英国二级和三级儿科糖尿病护理机构进行了此项研究,干预组培训13个团队79名医生(涉及359例年龄为4~15岁的1型糖尿